Welcome to Paid Research Studies


Browse Locations ... United States» ... California» ... Orange County





  • Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: ORMD-0801 (qd);   Drug: ORMD-0801 (bid);   Drug: ORMD-0801 (tid);   Other: Placebo
    Sponsors:   Oramed, Ltd.;   Integrium
    Recruiting - verified November 2016

  • Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2016

  • Condition:   Alzheimer's Disease
    Interventions:   Drug: LY3314814;   Drug: Placebo
    Sponsors:   Eli Lilly and Company;   AstraZeneca
    Recruiting - verified November 2016

  • Condition:   Dementia With Lewy Bodies
    Interventions:   Drug: RVT-101 35 mg;   Drug: RVT-101 70 mg;   Drug: Placebo
    Sponsor:   Axovant Sciences Ltd.
    Recruiting - verified December 2016

  • Condition:   Osteoarthritis
    Intervention:   Drug: Investigational Medical Product (IMP) administered in parent study
    Sponsors:   Pfizer;   Eli Lilly and Company
    Recruiting - verified November 2016

  • Conditions:   Chronic Pain;   Osteoarthritis, Hip;   Osteoarthritis, Knee
    Interventions:   Drug: NSAID;   Biological: Tanezumab 2.5 mg;   Biological: Tanezumab 5 mg
    Sponsor:   Pfizer
    Recruiting - verified November 2016

  • Condition:   Recurrent Osteosarcoma
    Interventions:   Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2016

  • Conditions:   Metastatic Malignant Neoplasm in the Lung;   Metastatic Osteosarcoma;   Recurrent Osteosarcoma
    Interventions:   Biological: Dinutuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Sargramostim
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Condition:   Alzheimer's Disease
    Interventions:   Drug: Aducanumab (BIIB037);   Drug: Aducanumab (BIIB037);   Drug: Placebo
    Sponsor:   Biogen
    Recruiting - verified November 2016

  • Condition:   Macular Degeneration
    Interventions:   Drug: abicipar pegol;   Drug: ranibizumab;   Other: sham procedure
    Sponsor:   Allergan
    Recruiting - verified November 2016

  • Condition:   Macular Degeneration
    Interventions:   Drug: abicipar pegol;   Drug: ranibizumab;   Other: sham procedure
    Sponsor:   Allergan
    Recruiting - verified November 2016

  • Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified April 2016

  • Condition:   CD33 Positive Acute Myelogenous Leukemia
    Intervention:   Biological: Antibody Drug Conjugate Chemotherapeutic
    Sponsor:   Pfizer
    Available - verified November 2016

  • Conditions:   Childhood Solid Neoplasm;   Metastatic Melanoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hodgkin Lymphoma;   Recurrent Melanoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdomyosarcoma;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2016

  • Conditions:   Adult Fibrosarcoma;   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Nerve Sheath Neoplasm;   PEComa;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma;   Synovial Sarcoma;   Undifferentiated (Embryonal) Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
    Interventions:   Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Classical Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
    Interventions:   Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Condition:   Heart Failure
    Intervention:   Device: Trends-equipped LifeVest 4000
    Sponsor:   Zoll Medical Corporation
    Recruiting - verified November 2016

  • Conditions:   Amyotrophic Lateral Sclerosis;   Frontal Temporal Dementia
    Interventions:   Drug: Memantine;   Drug: Placebo (for Memantine)
    Sponsor:   University of Kansas Medical Center
    Not yet recruiting - verified November 2016

  • Conditions:   Adult Solid Neoplasm;   Childhood Solid Neoplasm;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Central Nervous System Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2016

  • Conditions:   HIV;   Cancer;   Chronic Granulomatous Disease;   Dock 8 Deficiency
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2016

  • Conditions:   Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Childhood Central Nervous System Neoplasm;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified;   Recurrent Neuroblastoma;   Recurrent Solid Neoplasm
    Interventions:   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: WEE1 Inhibitor AZD1775
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Bacterial Infection;   Benign Neoplasm;   Malignant Neoplasm;   Methicillin-Resistant Staphylococcus Aureus Infection;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
    Interventions:   Drug: Chlorhexidine Gluconate;   Procedure: Wound Care Management;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma
    Interventions:   Biological: Dinutuximab;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Sargramostim;   Drug: Temozolomide;   Drug: Temsirolimus
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2016

  • Condition:   Thromboembolism
    Intervention:   Drug: Apixaban
    Sponsors:   Bristol-Myers Squibb;   Pfizer
    Recruiting - verified September 2016

  • Condition:   Cardiovascular Disease
    Interventions:   Drug: Methotrexate;   Drug: Placebo
    Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified November 2016

  • Condition:   Urinary Bladder, Neurogenic
    Interventions:   Drug: Fesoterodine PR 4 mg;   Drug: Fesoterodine PR 8 mg;   Drug: Fesoterodine PR 8 mg;   Drug: Oxybutynin;   Drug: Fesoterodine PR;   Drug: Fesoterodine BIC 2 mg;   Drug: Fesoterodine BIC 4 mg
    Sponsor:   Pfizer
    Recruiting - verified November 2016

  • Conditions:   Leukemia Cutis;   Myeloid Sarcoma;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Lymphoproliferative Syndrome;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
    Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting - verified November 2016

  • Conditions:   PRETEXT Stage 1 Hepatoblastoma;   PRETEXT Stage 2 Hepatoblastoma;   PRETEXT Stage 3 Hepatoblastoma;   PRETEXT Stage 4 Hepatoblastoma
    Interventions:   Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Procedure: Liver Transplantation;   Drug: Temsirolimus;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2016

  • Condition:   Heart Failure
    Intervention:   Device: ACUITY Spiral Left Ventricular Lead
    Sponsor:   Boston Scientific Corporation
    Recruiting - verified November 2016

  • Conditions:   Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma
    Intervention:   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Disseminated Neuroblastoma;   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Renal Cell Cancer;   Stage I Wilms Tumor;   Stage II Renal Cell Cancer;   Stage II Wilms Tumor;   Stage III Renal Cell Cancer;   Stage III Wilms Tumor;   Stage IV Renal Cell Cancer;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
    Interventions:   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Askin Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    Intervention:   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Acute Undifferentiated Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies;   Childhood Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hairy Cell Leukemia;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Neoplasm of Uncertain Malignant Potential;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
    Intervention:   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Condition:   Candidemia
    Interventions:   Drug: Anidulafungin;   Drug: Fluconazole
    Sponsor:   Pfizer
    Recruiting - verified November 2016